Business Context and Reporting Period
Company: NextCure, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2021
Reporting Period: Event-based disclosure regarding clinical data announcements and an upcoming investor event.
Key Financial Metrics
This filing is a regulatory disclosure of non-financial events (clinical data and investor communications). The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing discloses the following material developments:
- Clinical Data Announcement: On November 13, 2021, the Company announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting.
- Therapeutic Candidates: Data pertains to NC318 (a Siglec-15 antibody) and NC410 (a fusion protein of LAIR-2) for patients with advanced/metastatic solid tumors.
- Research Collaboration: Included a research study on NC410's impact on T cell activation and myeloid cell polarization conducted with the National Cancer Institute at the NIH.
Guidance, Outlook, and Management Commentary
Upcoming Events: The Company scheduled a Virtual Oncology Pipeline Update Event for November 15, 2021. A live webcast and subsequent replay were made available via the Company's website.
Legal Disclaimer: The information furnished in this Item 7.01, including the press release and investor presentation, is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Outlook: No specific financial guidance or quantitative outlook was provided in this text.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific clinical trial results and statistical significance of the data presented at SITC.
- Access the Virtual Oncology Pipeline Update presentation (Exhibit 99.2) for detailed pipeline timelines and strategic updates.
- Verify the Company's cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K does not contain financial statements.
- Monitor the Company's website for the archived webcast replay of the November 15, 2021 event.